Overview
CellarisBio offers the MICRO-TAG® platform, a reagent-based technology that quantifies ligand-target engagement in real-time within intact live cells, preserving native protein context. It supports drug discovery for challenging targets like degraders, molecular glues, and covalent inhibitors by providing quantitative fluorescent readouts compatible with standard workflows. Based in San Diego, California, the company delivers reagents and collaborative solutions for precision therapeutic development.
Frequently asked questions
- What is the MICRO-TAG platform?
- MICRO-TAG is a cellular target engagement technology that uses enzyme complementation to convert ligand-target interactions into measurable fluorescent signals in live cells, enabling real-time, quantitative assays.
- What drug discovery applications does CellarisBio support?
- The platform targets challenging modalities including degraders, molecular glues, and covalent inhibitors, aiding target validation, de-risking, and precision therapeutic discovery across diverse programs.
- Where is CellarisBio located and what solutions do they offer?
- CellarisBio is based in San Diego, California, USA, and provides MICRO-TAG reagents, real-time assay kits, and selective collaborative programs like the Open Target Initiative for academic and industry partners.